Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vera Bradley (VRA) Shares Outstanding (Diluted Average) (2016 - 2026)

Vera Bradley has reported Shares Outstanding (Diluted Average) over the past 17 years, most recently at $27.9 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Diluted Average) at $27.9 million for Q1 2026, down 3.57% from a year ago — trailing twelve months through Jan 2026 was $27.9 million (down 3.57% YoY), and the annual figure for FY2026 was $27.9 million, down 3.57%.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $27.9 million at Vera Bradley, roughly flat from $28.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for VRA hit a ceiling of $34.4 million in Q1 2022 and a floor of $27.8 million in Q2 2025.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $30.8 million (2023), compared with a mean of $30.4 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 1.54% in 2022 and later fell 9.42% in 2025.
  • Vera Bradley's Shares Outstanding (Diluted Average) stood at $31.7 million in 2022, then decreased by 1.26% to $31.3 million in 2023, then decreased by 6.33% to $29.3 million in 2024, then dropped by 4.62% to $28.0 million in 2025, then dropped by 0.29% to $27.9 million in 2026.
  • The last three reported values for Shares Outstanding (Diluted Average) were $27.9 million (Q1 2026), $28.0 million (Q4 2025), and $27.9 million (Q3 2025) per Business Quant data.